“I think initiating a conversation with a patient needs to start earlier, possibly even earlier than just at the point of giving them a diagnosis,” says Netty Kinsella, RN, MSc, PhD.
In this video, Marta Skrodzka, MD, PhD, FEBU, FECSM, FEAA, and Netty Kinsella, RN, MSc, PhD, discuss how urologists can help manage patients’ expectations when counseling on what side effects may arise from their prostate cancer treatments. This discussion is part of a larger forum on prostate cancer survivorship with Jai Seth, MD, BSc, MSc, FRCS. Skrodzka is a consultant urologist and Seth is a urology consultant at St George’s University Hospital, and Kinsella is a uro-oncology nurse consultant at the Royal Marsden NHS Foundation Trust in London, United Kingdom.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.